Name | Title | Contact Details |
---|
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion`s lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson`s disease (PD) and extending across the brain and affected organs.
EMD Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carterra, formerly Wasatch Microfluidics, develops high throughput surface plasmon resonance array-based platforms for biomolecular interaction analysis.
Spaltudaq Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.